MetaStat, a life science company focused on treating systemic metastasis, is focused on becoming an industry leader in the emerging field of personalized cancer therapy. Its proprietary platform technologies are the result of more than 15 years of collaboration with Albert Einstein College of Medicine of Yeshiva University, Massachusetts Institute of Technology (MIT), Cornell University, and Italy's IFO-Regina Elena Cancer Institute.
Metastatic cancer is the term given to cancer that has spread from where it first started to another place in the body. With 90% of all solid tumor cancer deaths due to metastasis, it is well understood that the medical community desperately needs the next-generation diagnostic and therapeutic products MetaStat specializes in developing. To learn more these products, visit www.metastat.com.
The company is led by a team of individuals who have accumulated a great deal of experience in the health care and financial industries. Warren C. Lau, founder and CEO of MetaStat, founded two other successful companies that currently list on the NYSE MKT and NASDAQ exchanges. The company's chief medical officer, Oscar Bronsther, M.D., is a Diplomat, American Board of Surgery; the Chairman, Section of General Surgery, at Inova Fairfax Hospital; and a Clinical Professor of Surgery at George Washington University in Washington, D.C.
A strong board of directors has also been assembled to advance the company's mission and objectives. Johan (Thijs) Spoor and Dr. Patrick Mooney are two notable members. Mr. Spoor is currently the CEO of FluoroPharma Medical (OTCQB: FPMI), a biopharmaceutical company focused on fulfilling the numerous unmet needs in diagnosis with its molecular imaging technology. He brings a background in nuclear pharmacy as well as finance and accounting. Prior to FluoroPharma, Mr. Spoor held the title of CFO for Sunstone BioSciences and was an equity research analyst at J.P. Morgan and Credit Suisse covering the biotechnology and medical device industries.
Dr. Mooney currently serves as the chief executive officer, president, and chairman of the board of directors of Echo Therapeutics, Inc. (NASDAQ: ECTE), a transdermal medical device company with deep expertise in advanced skin permeation technology. Prior to joining Echo Therapeutics, Dr. Mooney was president, chief executive officer, and chairman of Aphton Corp. (NASDAQ: APHT). Dr. Mooney also served as Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm, and as Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full service investment banking firm.
For more information on MetaStat and its ongoing efforts to help clinicians better customize cancer treatment, visit www.metastat.com
Sign up for "The Mission Report" at www.MissionIR.com